Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.70)
# 4,091
Out of 5,127 analysts
58
Total ratings
32%
Success rate
-26.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.29 | +247.95% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $5.82 | +89.00% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $23.14 | +33.97% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $2.17 | +775.58% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $7.10 | +195.77% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.45 | -8.17% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.95 | +443.29% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.17 | +10,200.43% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $26.31 | -4.98% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $78.10 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $2.37 | +84,288.19% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.24 | +466.80% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.31 | +88.32% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $15.45 | +288.35% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.47 | +308.16% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.28 | +204.88% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $2.02 | +11,810.67% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.79 | +6,429.62% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $3.41 | +58,587.17% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.73 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.21 | +397.93% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.78 | +139.18% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $13.75 | +76,263.64% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $4.11 | +800.24% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $43.51 | +589.50% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $812.77 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $110.58 | -19.52% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $140.54 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $0.83 | +1,802,784.62% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.68 | +19,959.70% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.09 | +340.64% | 1 | Mar 19, 2020 |
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.29
Upside: +247.95%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.82
Upside: +89.00%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $23.14
Upside: +33.97%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $2.17
Upside: +775.58%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $7.10
Upside: +195.77%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.45
Upside: -8.17%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.95
Upside: +443.29%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.17
Upside: +10,200.43%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $26.31
Upside: -4.98%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $78.10
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $2.37
Upside: +84,288.19%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.24
Upside: +466.80%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $5.31
Upside: +88.32%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $15.45
Upside: +288.35%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.47
Upside: +308.16%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.28
Upside: +204.88%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $2.02
Upside: +11,810.67%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.79
Upside: +6,429.62%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $3.41
Upside: +58,587.17%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $13.73
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.21
Upside: +397.93%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.78
Upside: +139.18%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $13.75
Upside: +76,263.64%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $4.11
Upside: +800.24%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $43.51
Upside: +589.50%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $812.77
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $110.58
Upside: -19.52%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $140.54
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $0.83
Upside: +1,802,784.62%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.68
Upside: +19,959.70%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.09
Upside: +340.64%